Next Article in Journal
Animals Experimentally Infected with SARS-CoV-2 Generate Functional Autoantibodies against G-Protein-Coupled Receptors
Previous Article in Journal
The Role of M1 and M2 Myocardial Macrophages in Promoting Proliferation and Healing via Activating Epithelial-to-Mesenchymal Transition
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Bleomycin Electrochemotherapy of Dermal Cylindroma as an Alternative Treatment in a Rare Adnexal Neoplasm: A Case Report and Literature Review

1
Department of Plastic and Regenerative Surgery, San Gallicano Dermatological Institute—IRCCS, 00144 Rome, Italy
2
Department of Oncologic and Preventative Dermatology, San Gallicano Dermatological Institute—IRCCS, 00144 Rome, Italy
3
Dermatopathological Laboratory, San Gallicano Dermatological Institute—IRCCS, 00144 Rome, Italy
4
Department of Maxillofacial Surgery, ACO San Camillo, Forlanini, 00152 Rome, Italy
5
Scientific & Medical Department, IGEA S.p.A, 41012 Carpi, Italy
*
Author to whom correspondence should be addressed.
Biomedicines 2023, 11(10), 2667; https://doi.org/10.3390/biomedicines11102667
Submission received: 15 August 2023 / Revised: 24 September 2023 / Accepted: 27 September 2023 / Published: 28 September 2023
(This article belongs to the Section Molecular and Translational Medicine)

Abstract

:
Background: Brooke–Spiegler syndrome is a rare autosomal dominant disorder characterized by the continuous development of multiple benign skin appendage tumors. It is treated usually by repeated standard surgery. Here, we present a case study where electrochemotherapy (ECT) with bleomycin was used as an effective alternative approach in treating advanced dermal cylindromatosis of the head and neck in a patient with Brooke–Spiegler syndrome. Patients and methods: A 45-year-old woman presented with multiple recurrent dermal cylindroma lesions on her scalp. Previous treatment consisted of several surgical excisions that resulted in psychological deterioration due to the formation of numerous scars and extensive alopecic areas. ECT was offered to provide tumor removal and disease control and to improve the patient’s quality of life. Results: The treatment was well tolerated, and a significant reduction in neoplastic tissue was achieved. Importantly, scalp skin condition significantly improved, regaining a fair follicular density on the margins. Conclusion: This report suggests the feasibility of bleomycin ECT as a less invasive alternative option for controlling multiple scalp cylindroma lesions with cosmetically acceptable results, and improving quality of life.

1. Introduction

Brooke–Spiegler syndrome (BSS) is a rare autosomal dominant disorder due to various mutations in the CYLD gene on chromosome 16q12-q13 [1]. Typically, this syndrome manifests after puberty, in adolescence and early adulthood, with the development of multiple benign skin appendage tumors, including cylindroma, spiradenoma, and trichoepithelioma. After the appearance of the first lesion, tumors progressively increase in size and number and accumulate throughout life. BSS seems to have greater expressivity in women, generally affecting several family members of the same generation [2]. Cylindromas are pink, smooth-surfaced, nodular tumoral lesions varying in size from a few millimeters to several centimeters; they can present as single or clustered nodules. Occasionally painful, these lesions mostly affect the scalp, face, and neck, but can also be found on the trunk and upper limbs. Multiple scalp lesions may confluence to form a ‘turban tumor’ lesion [3]. The malignant transformation of cylindromas is rare, but metastases in cases of malignancy are not uncommon [4]. Cylindromas are usually removed by radical surgical excision. Repeated surgical procedures are often necessary to control tumor burden, especially due to the high rate of recurrence. Furthermore, in a functional and aesthetic setting, the scalp and skin should be preserved as much as possible [5].
Electrochemotherapy (ECT) is a non-thermal local ablative treatment for solid neoplasms [6]. It is based on the combination of reversible electroporation (EP), the application of short, intense electric pulses, and the administration of a chemotherapeutic agent. Due to increased cell membrane permeability, the otherwise non-permeable chemotherapeutic agent can enter the cell; combining EP with chemotherapy generates a superior synergistic local cytotoxic effect. The most suitable drug for the clinical use of ECT is bleomycin, an antineoplastic agent frequently used to treat head and neck cancer [7]. The mechanism of action of bleomycin is to generate single- and double-stranded DNA breaks that lead to DNA fragmentation, chromosomal gaps, and deletions, and ultimately to mitotic cell death [8]. ECT exploits the presence of bleomycin in the target tumor at the time of electric pulse application to enhance the drug’s efficacy locally [9]. ECT has been shown to be highly effective in providing local tumor control and palliation of symptomatic lesions located in cutaneous or subcutaneous tissues, regardless of their histological origin, while maintaining a very low toxicity profile and high patient acceptance [10,11]. ECT is used as a neoadjuvant therapy with cytoreductive function: as a therapeutic option in unresponsive patients and/or when conventional treatments are not performed, and as a palliative therapy for highly vascularized nodules [12,13]. Further clinical evidence supports early ECT application to treat smaller lesions, improve efficacy, and eradicate multiple target nodules in a single treatment session, thus reducing the therapeutic burden on the patient [11].
Here, we present a case of a patient with multiple cylindromas of the scalp treated with bleomycin ECT, resulting in effective control of the disease with good aesthetic results. Therefore, we propose bleomycin ECT as an alternative therapeutic approach in BSS for benign skin appendage tumors, such as cylindromas.

2. Case Report

In December 2017, a 45-year-old woman presented at the Department of Plastic Surgery of San Gallicano Institute for the evaluation of multiple cancerous lesions on her scalp. The patient reported that the first lesion arose on her scalp at the age of 18 years, and, over time, several more lesions appeared and progressively increased in number and dimension, developing extensively on her face, trunk, and extremities. Since then, the patient underwent multiple surgical excisions at several locations, including the dorsal region of the trunk, the face in the preauricular region, and the scalp, in order to remove the nodules and minimize the aesthetic problem and physical discomfort caused by them. While effective in eliminating the nodules, the surgical treatments were all less aesthetically successful, leading to psychological deterioration due to the inevitable formation of numerous scars or multiple hypo/hyperpigmented scarring outcomes.
The first clinical examination of the patient at our institution showed about 60 rosy red, single, clustered, or confluent, painless nodular scalp lesions of variable size, ranging from 1 to 3 cm in diameter, with a firm-elastic consistency, mobile on the superficial and deep planes. On the face (glabellar, peri-nasal, and preauricular region) and the trunk (back and décolleté), there were numerous asymptomatic, small (2–5 mm in diameter) skin-colored papules. No malignant transformation features were noted. Based on clinical and histopathological evidence, the patient was diagnosed with BSS in 1990, when she was eighteen years old, and she removed the first lesion.
After receiving informed consent from the patient, tissue biopsies were obtained from four nodular lesions of the scalp and one small papule in the perinasal region. The histopathological analysis of the four nodules revealed typical features of a cutaneous cylindroma, and the examination of the small papule showed histological features of trichoepithelioma, overall confirming the diagnosis of BSS.
At that time, the extent of disease at the scalp site would have required the excision of large areas of the scalp, followed by reconstruction with dermo-epidermal grafts, large locoregional flaps, or a free flap. This is the reason for the idea of using ECT with bleomycin to test the response of cylindromas and evaluate the disease control rate, considering that the progressive growth of such lesions can turn into malignant transformation. ECT with bleomycin was offered as a less invasive alternative option to ensure tumor removal while avoiding further scarring and unpleasant cosmetic results. Another goal was to improve the patient’s quality of life (QoL) by reducing the number of surgical procedures and hospital visits. In March 2018, three large areas of the scalp with a high number of clustered or confluent lesions and a pre-auricular lesion on the face were treated with the first bleomycin ECT session at the operating block of San Gallicano Institute, IRCCS. The procedure lasted twenty minutes under mild sedation according to the European Standard Operating Procedures on Electrochemotherapy [14]. Briefly, bleomycin (Sanofi-Aventis S.p.A., Milano, Italy, vials of 15 mg) was administered intravenously at a dose of 15,000 UI/m2, followed by local application of high-voltage electrical pulses to each single tumor nodule. Type III hexagonal configuration electrodes were used. The electrical pulses (eight pulses of 100 ms duration) were delivered using a square-wave pulse generator (Cliniporator, IGEA S.p.A., Carpi, Italy). During the ECT procedure, a biopsy of one lesion (8 × 8 mm) was taken before treatment. A histopathological analysis showed that the multinodular lesion located in the scalp dermis was composed of small basaloid cells intermixed with paler cells with few lymphocytes. The presence of eosinophilic hyaline-like globules was evident. The epithelial cells were arranged as typical trabeculae/nests in a jigsaw puzzle pattern compatible with the cylindroma (Figure 1A). At greater magnification, the classic monomorphism of basophilic cells bordered by a thickened hyaline basal membrane was appreciated; the hyaline material, which exhibited a labyrinthine aspect in some areas, was interposed between the lobular structures (Figure 1B). All treated lesions were recorded with photographs to evaluate the aesthetic and functional results after treatment. The procedure was well tolerated, and no serious bleomycin ECT-related adverse events, such as pulmonary toxicity, were observed. Moderate facial edema was recorded in the postoperative period and treated with oral corticosteroids, showing resolution within 72 h. Other side effects included the following: moderate pain, well controlled with paracetamol 1000 mg, max three tablets per day; minimal skin toxicity with rare superficial ulcerations and modest alopecia at the margins of the treated areas. Daily dressings were performed by cleansing with a solution based on water-soluble sulfur, acetic acid, and Melaleuca alternifolia, and then treated with a spray based on hyaluronic acid sodium salt 0.2% (aluminum starch octenylsuccinate, hexamethyldisiloxane, sweet almond oil, vitamin E acetate, ximenynic acid, EO lemon, EO Melaleuca alternifolia, hyaluronic acid sodium salt, butane, isobutane, propane).
At 2 months following the first treatment, an objective response was observed in all the treated areas, with complete response achieved in 25% of the treated lesions and partial tumor regression (≥30% reduction in tumor size according to the RECIST criteria) in the remaining lesions. In November 2018, eight months after the first treatment, the patient underwent a second ECT session on the previously treated partially responsive nodules, and new lesions developed outside the treated area. The second treatment involved all lesions present on the scalp, face, and trunk.
Moderate edema, pain, skin ulceration, and alopecia were also detected after the second treatment session. Additional hyperpigmentation was observed mainly on the face and trunk and was managed with the application of lactoferrin-based iron-chelating creams and/or EDTA + vitamin C, with marked improvement after several months of application.
In April 2019, at 13 months after the first ECT treatment (5 months after the second session), a further reduction in neoplastic tissue was achieved by the sum of the effects of both treatments (Figure 2). Unfortunately, new lesions also appeared during this time because of the natural history of the disease, but no areas of malignant transformation were detected. Moderate scarring alopecia was observed in limited areas. If, before the treatment, the scalp appeared erythematous, reddish-pink, tight, thin, and alopecic, it regained a nearly normal skin tone, thickness, and elasticity in the post-treatment evaluation. Although it remained alopecic in the central areas, it recovered a fair follicular density on the margins.
This case report was approved by the central Ethical Committee IRCSS Lazio under the n° 1449/20. Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

3. Discussion

Cylindromas are very rare adnexal tumors, most frequently localized on the head and neck and often linked to Brooke–Spiegler syndrome. This report documents the safety and efficacy of bleomycin ECT in a patient with multiple benign skin adnexal tumors of the Brooke–Spiegler type. The treatment methods reported in the literature for cylindromas are mostly repeated non-demolishing surgical procedures. However, multiple scars from the repeated scalp excisions necessary to remove multiple lesions or large scars from extensive scalp resections can profoundly impact patients’ QoL [5]. Complete scalp resection followed by skin graft reconstruction is used for patients with familial cylindromatosis who are unresponsive, or unsuitable for other treatments. Although this strategy abolishes any possibility of the recurrence of scalp lesions, this treatment leads to complete scalp alopecia [15,16]. “Scalp-sparing” strategies include early primary excision and tumor enucleation [17], with a risk of recurrence after first-line treatment of about 35%. Mohs micrographic surgery is recommended for sporadic recurrent cases [5]. Hyfrecation or repeated laser treatment can be applied in selected small tumors [15,18]. Radiation therapy has also been proposed to treat this disorder, but patients with BSS may not benefit from its use. Several studies in the current literature have shown that this method may increase the risk of radiation-induced DNA damage and malignant transformation, and is therefore contraindicated [1,3,4]. Other reported therapeutic options include dermabrasion, cryotherapy, and radiofrequency [15], electrocoagulation, intralesional infiltration with triamcinolone acetonide, topical phenol, both topically and systemically applied acetylsalicylic acid, and topical 5% imiquimod cream [5,16]. However, most of these therapies can lead to scar formation and often have high recurrence rates. To date, most treatment strategies for scalp cylindromas have the disadvantage of leading to scar formation and functional impairment. Permanent alopecic areas where scar tissue replaces hair follicles can lead to significant changes in physical appearance, and, thus, psychological distress, especially in patients with a thick head of hair, as seen in the patient in this case report.
For these reasons, finding new or existing treatment modalities that have a selective, non-invasive effect on tumor tissue is essential. The efficacy of ECT has been largely reported in a wide variety of cutaneous and subcutaneous tumors, including non-melanoma skin cancers of the head and neck, such as squamous cell, basal cell, and Merkel cell carcinoma, melanoma metastases, and Kaposi sarcoma [10,11,19]. Because the cytotoxic effect of ECT is mostly limited to dividing tumor cells, in some cases, ECT may be both an organ- and a function-sparing modality [20] that allows for favorable aesthetic results [21]. Furthermore, ECT is a repeatable treatment with an associated increase in response rate [22]. To our knowledge, this is the first case report in which bleomycin ECT is proposed as an efficient and scalp-sparing alternative strategy in managing multiple cylindromas of the scalp. At the time of admission to the clinic, the patient would have needed an excision of extensive areas of the scalp. Instead, the choice of bleomycin ECT treatment was shown to be able to provide disease control. The treatment resulted in a cosmetically acceptable outcome, healthier skin appearance, limited scarring alopecic areas, and good preservation of hair follicles. In our case, using bleomycin ECT also improved the patient’s QoL by greatly reducing the hospitalization time and the number of repeated removal procedures. Longer follow-up and more extensive experience are needed to corroborate the value of this new approach. Although the rarity of the disease precludes broader observations, this case report presents a valuable strategy that could help to manage patients with BSS.

4. Conclusions

Bleomycin ECT represents an effective scalp-sparing alternative treatment for scalp cylindroma in patients with Brooke–Spiegler syndrome. A significant improvement in QoL was achieved, and the strategy reduced scarring and preserved hair follicles. Considering the results achieved in this case, the authors suggest that this method can be applied also in cases of large lesions of other anatomical areas, where surgical excision may damage function and/or aesthetics.

Author Contributions

All authors are responsible for the conception and design of the study, data interpretation, writing, revision, and the final approval of the manuscript. C.C. was responsible for the histopathological analysis of the multinodular scalp lesion biopsy. A.I. and V.S. were responsible for physical examination, the collection of medical history, and BSS diagnosis. A.B., F.A.G., T.P., and E.M. were responsible for conducting the study and for patient follow-up. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Italian Ministry of Health (RC2023).

Institutional Review Board Statement

This case report was approved by the central Ethical Committee IRCSS Lazio under the n° 1449/20. Written informed consent was obtained from the patient for the publication of this case report and for the use of any accompanying images.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

All data generated and analyzed during this study are available within the paper. Further inquiries can be directed to the corresponding author.

Acknowledgments

The authors thank Aashni Shah, Lara Vecchi, and Valentina Attanasio (Polistudium Srl, Milan Italy) for medical writing, editorial assistance, and language editing. They also thank the patient for granting permission to publish her medical case, including the accompanying images.

Conflicts of Interest

M.B. is an employee of IGEA S.p.A IGEA Spa, Carpi, Mo, Italy.

References

  1. Gutiérrez, P.P.; Eggermann, T.; Höller, D.; Jugert, F.K.; Beermann, T.; Grußendorf-Conen, E.I.; Frank, J. Phenotype diversity in familial cylindromatosis: A frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages. J. Investig. Dermatol. 2002, 119, 527–531. [Google Scholar] [CrossRef] [PubMed]
  2. Bowen, S.; Gill, M.; Lee, D.A.; Fisher, G.; Geronemus, R.G.; Vazquez, M.E.; Celebi, J.T. Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: Lack of genotype-phenotype correlation. J. Investig. Dermatol. 2005, 124, 919–920. [Google Scholar] [CrossRef]
  3. Rajan, N.; Ashworth, A. Inherited cylindromas: Lessons from a rare tumour. Lancet Oncol. 2015, 16, e460–e469. [Google Scholar] [CrossRef]
  4. Dubois, A.; Hodgson, K.; Rajan, N. Understanding inherited cylindromas clinical implications of gene discovery. Dermatol. Clin. 2017, 35, 61–71. [Google Scholar] [CrossRef]
  5. Rajan, N.; Trainer, A.H.; Burn, J.; Langtry, J.A. Familial cylindromatosis and brooke-spiegler syndrome: A review of current therapeutic approaches and the surgical challenges posed by two affected families. Dermatol. Surg. 2009, 35, 845–852. [Google Scholar] [CrossRef]
  6. Probst, U.; Fuhrmann, I.; Beyer, L.; Wiggermann, P. Electrochemotherapy as a new modality in interventional oncology: A review. Technol. Cancer Res. Treat. 2018, 17, 1533033818785329. [Google Scholar] [CrossRef]
  7. Brandt, J.P.; Gerriets, V. Bleomycin; StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar]
  8. Hecht, S.M. Bleomycin: New perspectives on the mechanism of action. J. Nat. Prod. 2000, 63, 158–168. [Google Scholar] [CrossRef] [PubMed]
  9. Bastrup, F.A.; Vissing, M.; Gehl, J. Electrochemotherapy with intravenous bleomycin for patients with cutaneous malignancies, across tumour histology: A systematic review. Acta Oncol. 2022, 61, 1093–1104. [Google Scholar] [CrossRef]
  10. Campana, L.G.; Testori, A.; Curatolo, P.; Quaglino, P.; Mocellin, S.; Framarini, M.; Bonadies, A. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. Eur. J. Surg. Oncol. 2016, 42, 1914–1923. [Google Scholar] [CrossRef]
  11. Clover AJ, P.; de Terlizzi, F.; Bertino, G.; Curatolo, P.; Odili, J.; Campana, L.G.; Gehl, J. Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019). Eur. J. Cancer 2020, 138, 30–40. [Google Scholar] [PubMed]
  12. Fabrizio, T.; Cagiano, L.; De Terlizzi, F.; Grieco, M.P. Neoadjuvant treatment by ECT in cutaneous malignant neoplastic lesions. J. Plast. Reconstr. Aesthet. Surg. 2020, 73, 904–912. [Google Scholar] [CrossRef]
  13. Jarm, T.; Cemazar, M.; Miklavcic, D.; Sersa, G. Antivascular effects of electrochemotherapy: Implications in treatment of bleeding metastases. Expert Rev. Anticancer Ther. 2010, 10, 729–746. [Google Scholar]
  14. Gehl, J.; Sersa, G.; Matthiessen, L.W.; Muir, T.; Soden, D.; Occhini, A.; Mir, L.M. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol. 2018, 57, 874–882. [Google Scholar]
  15. Lucas-Truyols, S.; Lloret-Ruiz, C.; Millán-Parrilla, F.; Gimeno-Carpio, E. A Simple and Effective Method for Treating Cylindromas in Brooke-Spiegler Syndrome. Actas Dermosifiliogr. 2017, 108, 692–694. [Google Scholar] [CrossRef]
  16. Parren, L.J.; Ferdinandus, P.; van der Hulst, R.; Frank, J.; Tuinder, S. A novel therapeutic strategy for turban tumor: Scalp excision and combined reconstruction with artificial dermis and split skin graft. Int. J. Dermatol. 2014, 53, 246–249. [Google Scholar] [CrossRef]
  17. Brass, D.; Rajan, N.; Langtry, J. Enucleation of Cylindromas in Brooke-Spiegler Syndrome: A Novel Surgical Technique. Dermatol. Surg. 2014, 40, 1438–1439. [Google Scholar] [CrossRef]
  18. Retamar, R.A.; Stengel, F.; Saadi, M.E.; Kien, M.C.; Della Giovana, P.; Cabrera, H.; Chouela, E.N. Brooke-Spiegler syndrome—Report of four families: Treatment with CO2 laser. Int. J. Dermatol. 2007, 46, 583–586. [Google Scholar] [CrossRef]
  19. Bertino, G.; Sersa, G.; De Terlizzi, F.; Occhini, A.; Plaschke, C.C.; Groselj, A.; Benazzo, M. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur. J. Cancer 2016, 63, 41–52. [Google Scholar] [CrossRef] [PubMed]
  20. Kis, E.G.; Baltás, E.; Ócsai, H.; Vass, A.; Németh, I.B.; Varga, E.; Tóth-Molnár, E. Electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinomas. Sci. Rep. 2019, 9, 4285. [Google Scholar] [CrossRef] [PubMed]
  21. Bonadies, A.; Bertozzi, E.; Cristiani, R.; Govoni, F.A.; Migliano, E. Electrochemotherapy in Skin Malignancies of Head and Neck Cancer Patients: Clinical Efficacy and Aesthetic Benefits. Acta Dermato-Venereol. 2019, 99, 1246–1252. [Google Scholar] [CrossRef] [PubMed]
  22. Quaglino, P.; Mortera, C.; Osella-Abate, S.; Barberis, M.; Illengo, M.; Rissone, M.; Bernengo, M.G. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann. Surg. Oncol. 2008, 15, 2215–2222. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Histopathological analysis of the scalp lesion before ECT treatment (H&E stain). The dermal proliferation of basaloid cells arranged in a nest with the typical “jigsaw” puzzle pattern compatible with cylindroma (×40) (A). Higher magnification of the dotted rectangle region (×200) shows that each nest is composed of a palisading peripheral lining of smaller basophilic cells (black arrows), an inner population with larger and more differentiated paler cells (stars), and shows the presence of eosinophilic hyaline-like globules (yellow arrows). The nests are surrounded by a thickened eosinophilic hyalinized basement membrane material (arrowheads) (B).
Figure 1. Histopathological analysis of the scalp lesion before ECT treatment (H&E stain). The dermal proliferation of basaloid cells arranged in a nest with the typical “jigsaw” puzzle pattern compatible with cylindroma (×40) (A). Higher magnification of the dotted rectangle region (×200) shows that each nest is composed of a palisading peripheral lining of smaller basophilic cells (black arrows), an inner population with larger and more differentiated paler cells (stars), and shows the presence of eosinophilic hyaline-like globules (yellow arrows). The nests are surrounded by a thickened eosinophilic hyalinized basement membrane material (arrowheads) (B).
Biomedicines 11 02667 g001
Figure 2. Multiple cylindroma lesions localized on the scalp treated with bleomycin ECT. Baseline presentation before starting bleomycin ECT (A); at 1 year after bleomycin ECT (B).
Figure 2. Multiple cylindroma lesions localized on the scalp treated with bleomycin ECT. Baseline presentation before starting bleomycin ECT (A); at 1 year after bleomycin ECT (B).
Biomedicines 11 02667 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bonadies, A.; Iorio, A.; Silipo, V.; Cota, C.; Govoni, F.A.; Battista, M.; Pallara, T.; Migliano, E. Bleomycin Electrochemotherapy of Dermal Cylindroma as an Alternative Treatment in a Rare Adnexal Neoplasm: A Case Report and Literature Review. Biomedicines 2023, 11, 2667. https://doi.org/10.3390/biomedicines11102667

AMA Style

Bonadies A, Iorio A, Silipo V, Cota C, Govoni FA, Battista M, Pallara T, Migliano E. Bleomycin Electrochemotherapy of Dermal Cylindroma as an Alternative Treatment in a Rare Adnexal Neoplasm: A Case Report and Literature Review. Biomedicines. 2023; 11(10):2667. https://doi.org/10.3390/biomedicines11102667

Chicago/Turabian Style

Bonadies, Antonio, Alessandra Iorio, Vitaliano Silipo, Carlo Cota, Flavio Andrea Govoni, Michela Battista, Tiziano Pallara, and Emilia Migliano. 2023. "Bleomycin Electrochemotherapy of Dermal Cylindroma as an Alternative Treatment in a Rare Adnexal Neoplasm: A Case Report and Literature Review" Biomedicines 11, no. 10: 2667. https://doi.org/10.3390/biomedicines11102667

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop